Reuters Health Report

Click to View in Browser 02/20/2014 GlaxoSmithKline's COPD drug Anoro receives European green light LONDON (Reuters) - Anoro, a combination drug for chronic obstructive pulmonary disease (COPD) developed by GlaxoSmithKline and Theravance, has received the green light from European regulators, the companies said on Thursday. Raptor says brain disorder drug slows loss of muscle control in study (Reuters) - Raptor Pharmaceutical Corp said its experimental brain disorder drug slowed the loss of muscle control in patients with Huntington's disease after 18 months of treatment. Exclusive: Bayer, Novartis, others eye Merck's consumer health unit - sources NEW YORK/LONDON (Reuters) - A handful of consumer and healthcare companies including Bayer AG and Novartis are exploring a deal for Merck & Co Inc's consumer healthcare business, as they seek to gain scale in a fragmented industry, according to several people familiar with the matter. Nepal must toughen fight on women's "fallen womb" crisis -Amnesty KATHMANDU, Feb 20 (Thomson Reuters Foundation) - When pregnant Nepali teenager Reena Pokharel began labor in her remote village, her family consulted a soothsayer, pressed her stomach and told her to cough to force the baby out. Can avatars bring out the good in gamers? NEW YORK (Reuters Health) - Taking on the role of a game avatar like the benevolent Superman or villainous Voldemort may influence a person's behavior after the game is over, according to a new study. Teens who text about condoms more likely to use them NEW YORK (Reuters Health) - High school students who discussed condoms or another form of birth control via text or other technology were almost four times as likely to use condoms when they had sex, a new study shows. Ranbaxy and Teva settle with NY Attorney General over collusion (Reuters) - The New York Attorney General and the U.S. units of Ranbaxy Laboratories Ltd and Teva Pharmaceutical Industries Ltd have settled claims that an agreement between the two drugmakers unlawfully restricted competition. Lilly lung cancer drug improves survival in late-stage trial (Reuters) - An experimental cancer drug developed by Eli Lilly and Co, touted by some to be the company's next blockbuster, significantly improved survival rates in lung cancer patients, sending the company's shares up 3 percent in early trading. Poor sleep linked to widespread pain NEW YORK (Reuters Health) - Regularly feeling tired and worn out after a night's sleep was the strongest predictor of also developing widespread pain in a new study of UK adults over the age of 50. Sitting tied to disability among older Americans: study NEW YORK (Reuters Health) - Regardless of how much time older Americans spend being active, those who sit for more hours each day are more likely to be disabled, according to a new study. Related Video Vienna study gives voice to elephant rumblings For competing jackdaws, the eyes have it The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today   A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today   » MORE NEWSLETTERS

- 3 Times Square New York, NY 10036 USA © Copyright 2010 Thomson Reuters Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book. Details Subscribe to other Reuters newsletters. Unsubscribe from this newsletter. Follow us on Twitter Friend us on Facebook Forward to a friend